RemeGen Co., Ltd., a leader in biopharmaceutical innovation based in China, has unveiled promising results from its Phase I/II clinical study of RC88, a first-in-class antibody-drug conjugate (ADC), at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) in Chicago. The study focuses on the efficacy and safety of RC88 in treating advanced solid […]
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released pivotal new data from its Phase 2b HERIZON-BTC-01 clinical trial assessing zanidatamab in previously treated HER2-positive biliary tract cancer (BTC). The study’s findings were prominently featured at the American Society of Clinical Oncology (ASCO) Annual Meeting today, highlighting significant improvements in overall survival rates and continued positive responses […]
Eli Lilly and Company (Lilly, NYSE: LLY) has released updated data from its ongoing Phase 1/2 clinical trial for olomorasib, showcasing significant advancements in the treatment of advanced solid tumors with KRAS G12C mutations. The data, which highlights both monotherapy and combination therapy results with Merck’s KEYTRUDA (pembrolizumab), was presented at the prestigious 2024 American […]
Rakuten Medical, Inc., a pioneer in biotechnology focusing on precision, cell-targeting photoimmunotherapy, unveiled updated interim results from its Phase 1b/2 study of ASP-1929 photoimmunotherapy in combination with anti-PD-1 therapy. The data, presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) on June 2, 2024, provides new insights into the treatment of […]
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical leader focused on innovative therapy developments, has revealed Phase 1 clinical data suggesting long-term efficacy and a manageable safety profile for its novel peptide drug conjugate (PDC), sudocetaxel zendusortide (TH1902). The findings will be shared during a poster session at the 2024 American Society of Clinical Oncology […]
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a trailblazer in developing small molecule therapeutics for cancer, has released the final results of its Phase 1 trial combining azenosertib with gemcitabine for relapsed or refractory osteosarcoma. The study findings, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, showcased a notable improvement in […]